PharmaShots | Incisive News in 3 Shots

Subscribe Now

JW Therapeutics

$JW Therapeutics Receives the NMPA’s IND Clearance of Carteyva (relmacabtagene autoleucel) for Moderately or Severely Refractory Systemic Lupus Erythematosus$

JW Therapeutics Receives the NMPA’s IND Clearance of Carteyva (relmacabtagene autoleucel) for Moderately or Severely Refractory Sy...

April 11, 2023

JW Therapeutics Initiates Clinical Study of JWATM214 for the Treatment of Advanced Hepatocellular Carcinoma

JW Therapeutics Initiates Clinical Study of JWATM214 for the Treatment of Advanced Hepatocellular Carcinoma

February 28, 2023

$JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicular Lymphoma$

JW Therapeutics Receives the NMPA’s Approval for Carteyva (relmacabtagene autoleucel) sNDA to Treat Relapsed or Refractory Follicu...

October 11, 2022

JW Therapeutics Reports Initiation of P-I clinical study for JWATM204 to Treat Advanced Hepatocellular Carcinoma

JW Therapeutics Reports Initiation of P-I clinical study for JWATM204 to Treat Advanced Hepatocellular Carcinoma

July 5, 2022

JW Therapeutics Receives the NMPA’s IND Clearance for the Clinical Trial of Carteyva (relmacabtagene autoleucel) as 2L Treatment of Large B-Cell Lymphoma

JW Therapeutics Receives the NMPA’s IND Clearance for the Clinical Trial of Carteyva (relmacabtagene autoleucel) as 2L Treatment o...

March 31, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us